SYMFI FDA approval date

The FDA approved SYMFI on 22 Mar 2018.

FDA approval date
22 Mar 2018

Drug identity has not yet been verified against registry records

Also recorded as EFAVIRENZ; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE

Included trials

No linked trials for this drug yet. Browse all trials

PDUFA dates and FDA decisions

Date as reportedDrug / companyEventConditionEvidence
2018-03-22DaySYMFIFDA original application approvalFDA approval decisionNot specifiedOpen original source
Read source excerpt

{"application_number": "NDA022142", "applicant_as_listed_by_fda": "MYLAN LABS LTD", "brand_names": ["SYMFI"], "active_ingredients": ["EFAVIRENZ", "LAMIVUDINE", "TENOFOVIR DISOPROXIL FUMARATE"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20180322", "matched_on": "drug record created from this FDA brand name"}

First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026